Holmen Bob
Known title: DirectorCIK: 0001843508
Associated companies
Transaction History
| FTH | ▲ Buy | Grant | 4,466 | $0 | 7/10/2023 | View on chart |
| FTH | ▲ Buy | Grant | 4,466 | $0 | 6/10/2022 | View on chart |
| FTH | ▲ Buy | Grant | 4,466 | $0 | 7/10/2023 | View on chart |
| FTH | ▲ Buy | Grant | 4,466 | $0 | 6/10/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
William Blair Begins Coverage of Faeth Therapeutics (FTH)
William Blair has started coverage of Faeth Therapeutics and issued an Outperform rating. The move may increase analyst attention and could influence market perception. The stock is currently trading below its 52‑week low and has a low RSI, indicating it is in a downtrend.
William Blair Begins Coverage of Faeth Therapeutics (FTH). William Blair has started coverage of Faeth Therapeutics and issued an Outperform rating. The move may increase analyst attention and could influence market perception. The stock is currently trading below its 52‑week low and has a low RSI, indicating it is in a downtrend.